A diaziridine-based tumor-activated prodrug for AKR1C3-expressing cancers from a defunct Bay Area biotech. OBI-3424 (formerly TH-3424) is a tumor-activated prodrug in Ph. II that releases DNA-crosslinking diaziridine phosphamide (remniscent of thioTEPA) upon activation by the NAD(P)H-dependent aldoketoreductase, AKR1C3, which is differentially expressed in many cancers. The molecule was originated at...
A diaziridine-based tumor-activated prodrug for AKR1C3-expressing cancers from a defunct Bay Area biotech.
OBI-3424
IV AKR1C3-activated cytotoxin prodrug Ph. I/II in advanced solid tumors prodrug of DNA cross-linking agent Br. J. Cancer, May 12, 2023 OBI Pharma, TW; Threshold Pharma, CA
Editor:
Loading...
